News
  Date Title View
Dec 19, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Judi...
Dec 7, 2016
- Trial On Track for Topline 90-day Efficacy Readout in Q2 2017 - IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today annou...
Dec 1, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that company management will participate in the following conferences in D...
Nov 3, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that company management will present an overview of the company at the fol...
Nov 2, 2016
- New Data Adds Further Positive Insight into RhopressaTM and RoclatanTM Potential - - Company Closes the Third Quarter with Over $255 million in Cash and Investments - Conference Call and Webcast Today, November 2, at 5:00 p.m. ET IRVINE, Calif.--(BU...
Oct 27, 2016
- Study Successfully Achieves Primary Efficacy Endpoint - - Company Separately Announces Withdrawal of RhopressaTM NDA, with the Expectation of Refiling in January 2017 - Conference Call and Webcast Today, October 27, at 5:00 p.m. ET IRVINE, Calif.--(BUSINESS ...
Oct 25, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), (the "Company"), announced today that its third quarter 2016 financial results will be released after the market closes on Wednesday, November 2, 2016. Following the release, the Company will host a live conference call and webcast at ...
Sep 28, 2016
Webcast to Begin at 12:00p.m. Eastern Time IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), today announced that the Company will host a live webcast of its Investor Day taking place on Wednesday, October 5, 2016 at 12:00p.m. ET in New York, NY. ...
Sep 16, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the pricing of a regist...
Sep 15, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that it has commenced a...
Page: FirstPrevious
4
NextLast
= add release to Briefcase